Company: MBIO
Filing Date: 2025-01-22
Form Type: DEF 14C
Source: 0001104659-25-005251
Chunk: 2

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-22
Form: DEF 14C
Chunk 2
---
holder meeting will be held to consider any matter which is described herein. We are not asking you for a consent or proxy and you are requested not to send us a consent or proxy.

| January 22, 
 2025        | By Order of the Board of Directors,                                    |
|:------------|:-----------------------------------------------------------------------|
|             | /s/ Manuel Litchman, M.D.                                              |
|             | Manuel Litchman, M.D.                                                  |
|             | President, Chief Executive Officer and Interim Chief Financial Officer |

<div align='center'>MUSTANG BIO, INC.

377 Plantation Street, 1st Floor
Worcester, MA 01605

INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</div>

This Information Statement
(this “Information Statement”) is being mailed to the holders of record at the close of business on January 14, 2025 (the
“Record Date”) of the shares of common stock, par value $0.0001 per share, of Mustang Bio, Inc., a Delaware corporation (“Mustang,”
“we,” “our,” “us,” or the “Company”), in connection with the actions taken by written
consent of the Majority Holders in lieu of a meeting to approve the actions described in this Information Statement.

The Majority Holders, beneficially owning 6,552,781 shares of our issued and outstanding common stock and 250,000 shares of our issued and outstanding Class A Preferred Stock, have executed the Written Consent approving the Warrant ShareIssuance. The Majority Holders
held of record on the Record Date approximately 57% of the voting power necessary to approve the proposed Warrant Share Issuance. Dissenting
stockholders do not have any statutory appraisal rights as a result of the actions taken. The Board does not intend to solicit any proxies
or consents from any other stockholders in connection with this action. All necessary corporate approvals have been obtained, and this
Information Statement is furnished solely to advise stockholders of the action taken by the Written Consent.

Section 228 of the DGCL generally
provides in substance that unless a company’s certificate of incorporation provides otherwise, stockholders may take any action
without a meeting of stockholders, without prior notice and without a vote if a consent or consents in writing, setting forth the action
so taken, is signed by holders of the